Recent advancements in genetics have revolutionized the ability to study chromosomes at a quick level. array Comparative Genomic Hybridization (aCGH) emerges as a potential tool capable of pinpointing the specific type of cancer by studying the abnormalities in the chromosomes. The ability to identify the primary source of cancer holds significant importance in cases of CUP, as it correlates with the development of more effective treatment protocols.
RGCC array Comparative Genomic Hybridization (aCGH) test reveals the structural abnormalities present within the genome. It is a cytogenetic assay used for the detection of chromosomal abnormalities. It is an easy and quick method requiring CTCs from a patient blood sample.
Through advanced comparative genome hybridization techniques, this test offers invaluable insights into the patient’s genetic makeup, RGCC aCGH scrutinizes the patient’s DNA for abnormalities and malfunctions, providing personalized chromosomal analysis results, and guiding clinical decisions with precision to find the primary origin of the tumour.
Chromosomal abnormalities: Genetic abnormalities have been associated with different diseases including cancer. Genomic aberrations might contribute to tumorigenesis and have been connected with the progression of the diseases. It enables oncologists and clinicians to gain insights into the patient’s genetic profile, identify potential cancer risk factors, and determine optimal treatment strategies.
Primary origin of the tumor: Identifying the primary origin of cancer in cases of unknown primary origin is essential for guiding treatment decisions, predicting outcomes, and monitoring the disease. aCGH test is beneficial when the primary origin of the cancer tumor is unknown. In such a case, the aCGH test helps identify chromosomal abnormalities to help detect the location of the cancer.
aCGH, array Comparative Genomic Hybridization test designed to identify the location of the primary tumor and detect chromosomal abnormalities helps identify chromosomal abnormalities associated with specific types of cancer. The test is used to detect carcinoma of unknown primary origin.
The first step towards personalized cancer care is scheduling an appointment with us.
Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.
We guide you through the process of selecting the most effective tests for your specific cancer.
We deliver precise results that guide treatment decisions and enhance outcomes.
“With RGCC’s aCGH test, I can predict primary tumor location from multiple tumours through genetic abnormalities. This information is crucial for primary treatment planning, ensuring optimal outcomes and patient well-being. A vital tool in modern oncology.”
Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.
RGCC aCGH test is performed to identify the abnormalities in chromosomes that are associated with different types of cancer.
Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.
Absolutely, tests can be performed while undergoing treatment to assess the effectiveness of the treatment against cancer.
Your blood sample undergoes processing in cutting-edge laboratories by scientists and technicians to deliver insights into your cancer cells.
Yes, all RGCC tests utilize blood samples. However, certain cancers, like glioblastoma and brain tumors, may require additional samples such as CSF or tissue. Otherwise, a peripheral blood sample alone is enough.
Yes, tests like aCGH can pinpoint the origin of an unknown primary tumor by analyzing genetic abnormalities present in tumor cells.
RGCC Metastat is an effective test for identifying secondary tumors development and its potential location. It helps detect secondary tumors through analyzing Circulating Tumor Cells (CTCs) in the bloodstream. The test provides valuable insights into disease progression and metastasis.
Tests personalize treatment regimens by providing crucial information on drugs and therapies tailored to effectively target cancer cells.
Circulating Tumor Cells (CTCs) are cancer cells that have detached from the primary tumor and circulate in the bloodstream. Cancer Stem Cells (CSCs) are a subpopulation of CTCs and both serve as biomarkers for cancer.
Tests like ChemoSNiP and CAMBISeq provide information on the body’s response to the drugs and sensitivity to immunotherapy.
Still unsure about the location of your tumor? aCGH is the right test for you! This test detects chromosomal abnormalities to reveal the location of your tumor. Take the aCGH test today and gain clarity on your cancer diagnosis.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
Copyright 2024 © All Right Reserved.
Designed by Bee High Media